Subtitle
Biochemical Results, Toxicity, Patient QoL After Delivery of Dose-Escalated Image Guided PT for Prostate Cancer
Subtitle
Biochemical Results, Toxicity, Patient QoL After Delivery of Dose-Escalated Image Guided PT for Prostate Cancer
Proto therapy Time
February 2016
Executive summary
A large series of 1327 localized prostate cancer patients reported 5-year biochemical control rate, toxicity and patient-reported quality of life after proton therapy.
The study concluded that image guided proton therapy provided excellent biochemical control rates and the actuarial rates of high-grade toxicity were low.
Key content topics
Top cancer treatments
Related contents
Proton Therapy Publication
March 2024
A multicenter high-quality data registry for advanced proton therapy approaches: the POWER registry.
Proton Therapy Publication
April 2024
FLASH Radiotherapy: What Can FLASH's Ultra High Dose Rate Offer to the Treatment of Patients With Sarcoma?
Proton Therapy Publication
April 2024
Proton FLASH radiotherapy ameliorates radiation-induced salivary gland dysfunction and oral mucositis and increases survival in a mouse model of head and neck cancer.
Proton Therapy Publication
April 2024
Comprehensive radiotherapy for pediatric Ewing Sarcoma: Outcomes of a prospective proton study.
Proton Therapy Publication
March 2024
Photon vs proton hypofractionation in prostate cancer: A systematic review and meta-analysis. This review.
Proton Therapy Publication
February 2024
Prospective study investigating hypofractionated proton beam therapy in patients with inoperable early stage non-small cell lung cancer.
Proton Therapy Publication
April 2024
Long-term survival outcomes and quality of life of image-guided proton therapy for operable stage I non-small cell lung cancer: A phase 2 study.
Proton Therapy Publication
March 2024
Efficacy and toxicity of photon, proton, and carbon ion radiotherapy in the treatment of intracranial solitary fibrous tumor/hemangiopericytoma.
Proton Therapy Publication
January 2024
Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy.